138 related articles for article (PubMed ID: 18585509)
1. Correlates of late and very late thrombosis of drug eluting stents.
Mishkel GJ; Moore AL; Markwell S; Shelton ME
Am Heart J; 2008 Jul; 156(1):141-7. PubMed ID: 18585509
[TBL] [Abstract][Full Text] [Related]
2. Impact of early versus late clopidogrel discontinuation on stent thrombosis following percutaneous coronary intervention with first- and second-generation drug-eluting stents.
Loh JP; Torguson R; Pendyala LK; Omar A; Chen F; Satler LF; Pichard AD; Waksman R
Am J Cardiol; 2014 Jun; 113(12):1968-76. PubMed ID: 24767975
[TBL] [Abstract][Full Text] [Related]
3. Predictors of early, late, and very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction.
Brodie B; Pokharel Y; Garg A; Kissling G; Hansen C; Milks S; Cooper M; McAlhany C; Stuckey T
JACC Cardiovasc Interv; 2012 Oct; 5(10):1043-51. PubMed ID: 23078734
[TBL] [Abstract][Full Text] [Related]
4. Thrombosis of second-generation drug-eluting stents in real practice results from the multicenter Spanish registry ESTROFA-2 (Estudio Español Sobre Trombosis de Stents Farmacoactivos de Segunda Generacion-2).
de la Torre Hernández JM; Alfonso F; Gimeno F; Diarte JA; Lopez-Palop R; Pérez de Prado A; Rivero F; Sanchis J; Larman M; Diaz JF; Elizaga J; Moreiras JM; Gomez Jaume A; Hernández JM; Mauri J; Recalde AS; Bullones JA; Rumoroso JR; Del Blanco BG; Baz JA; Bosa F; Botas J; Hernández F;
JACC Cardiovasc Interv; 2010 Sep; 3(9):911-9. PubMed ID: 20850089
[TBL] [Abstract][Full Text] [Related]
5. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents.
Nakazawa G; Finn AV; Vorpahl M; Ladich ER; Kolodgie FD; Virmani R
J Am Coll Cardiol; 2011 Jan; 57(4):390-8. PubMed ID: 21251578
[TBL] [Abstract][Full Text] [Related]
6. Incidence and predictors of very late (>or=4 years) major cardiac adverse events in the DESIRE (Drug-Eluting Stents in the Real World)-Late registry.
Costa JR; Sousa A; Moreira AC; Costa RA; Cano M; Maldonado G; Campos C; Carballo M; Pavanello R; Sousa JE
JACC Cardiovasc Interv; 2010 Jan; 3(1):12-8. PubMed ID: 20129562
[TBL] [Abstract][Full Text] [Related]
7. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.
Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Cheong SS; Kim JJ; Park SW; Park SJ
JACC Cardiovasc Interv; 2008 Oct; 1(5):494-503. PubMed ID: 19463351
[TBL] [Abstract][Full Text] [Related]
8. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos).
de la Torre-Hernández JM; Alfonso F; Hernández F; Elizaga J; Sanmartin M; Pinar E; Lozano I; Vazquez JM; Botas J; Perez de Prado A; Hernández JM; Sanchis J; Nodar JM; Gomez-Jaume A; Larman M; Diarte JA; Rodríguez-Collado J; Rumoroso JR; Lopez-Minguez JR; Mauri J;
J Am Coll Cardiol; 2008 Mar; 51(10):986-90. PubMed ID: 18325436
[TBL] [Abstract][Full Text] [Related]
9. Correlates and outcomes of late and very late drug-eluting stent thrombosis: results from DESERT (International Drug-Eluting Stent Event Registry of Thrombosis).
Waksman R; Kirtane AJ; Torguson R; Cohen DJ; Ryan T; Räber L; Applegate R; Waxman S; Gordon P; Kaneshige K; Leon MB;
JACC Cardiovasc Interv; 2014 Oct; 7(10):1093-102. PubMed ID: 25240540
[TBL] [Abstract][Full Text] [Related]
10. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
Sarno G; Lagerqvist B; Fröbert O; Nilsson J; Olivecrona G; Omerovic E; Saleh N; Venetzanos D; James S
Eur Heart J; 2012 Mar; 33(5):606-13. PubMed ID: 22232428
[TBL] [Abstract][Full Text] [Related]
11. Angiographic predictors of 2-year stent thrombosis in patients receiving drug-eluting stents: Insights from the ADAPT-DES study.
Généreux P; Redfors B; Witzenbichler B; Maehara A; Yadav M; Weisz G; Francese DP; Parvataneni R; Brener SJ; Mehran R; Kirtane AJ; Stone GW
Catheter Cardiovasc Interv; 2017 Jan; 89(1):26-35. PubMed ID: 26813732
[TBL] [Abstract][Full Text] [Related]
12. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
[TBL] [Abstract][Full Text] [Related]
13. Rates of stent thrombosis in bare-metal versus drug-eluting stents (from a large Australian multicenter registry).
Yan BP; Duffy SJ; Clark DJ; Lefkovits J; Warren R; Gurvitch R; Lew R; Sebastian M; Brennan A; Andrianopoulos N; Reid CM; Ajani AE;
Am J Cardiol; 2008 Jun; 101(12):1716-22. PubMed ID: 18549846
[TBL] [Abstract][Full Text] [Related]
14. Second-generation versus first-generation drug-eluting stents for the treatment of patients with acute coronary syndromes and obstructive coronary artery disease.
Machado C; Raposo L; Dores H; Leal S; Campante Teles R; de Araújo Gonçalves P; Mesquita Gabriel H; Almeida M; Mendes M
Coron Artery Dis; 2014 May; 25(3):208-14. PubMed ID: 24419038
[TBL] [Abstract][Full Text] [Related]
15. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study.
Naidu SS; Krucoff MW; Rutledge DR; Mao VW; Zhao W; Zheng Q; Wilburn O; Sudhir K; Simonton C; Hermiller JB
JACC Cardiovasc Interv; 2012 Jun; 5(6):626-35. PubMed ID: 22721657
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.
Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Stanco G; Rosato G; Suryapranata H; De Luca G
JACC Cardiovasc Interv; 2014 Aug; 7(8):849-56. PubMed ID: 25147029
[TBL] [Abstract][Full Text] [Related]
17. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.
Tada T; Byrne RA; Simunovic I; King LA; Cassese S; Joner M; Fusaro M; Schneider S; Schulz S; Ibrahim T; Ott I; Massberg S; Laugwitz KL; Kastrati A
JACC Cardiovasc Interv; 2013 Dec; 6(12):1267-74. PubMed ID: 24355117
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome after drug eluting stenting in patients with ST-segment elevation myocardial infarction: data from the REAL registry.
Campo G; Saia F; Percoco G; Manari A; Santarelli A; Vignali L; Varani E; Benassi A; Sangiorgio P; Tarantino F; Magnavacchi P; De Palma R; Guastaroba P; Marzocchi A
Int J Cardiol; 2010 Apr; 140(2):154-60. PubMed ID: 19056134
[TBL] [Abstract][Full Text] [Related]
19. Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry.
Berger PB; Kleiman NS; Pencina MJ; Hsieh WH; Steinhubl SR; Jeremias A; Sonel A; Browne K; Barseness G; Cohen DJ;
JACC Cardiovasc Interv; 2010 Sep; 3(9):920-7. PubMed ID: 20850090
[TBL] [Abstract][Full Text] [Related]
20. Comparison of late (3-year) registry data outcomes using bare metal versus drug-eluting stents for treating ST-segment elevation acute myocardial infarctions.
Assali A; Vaduganathan M; Vaknin-Assa H; Lev EI; Brosh D; Teplitsky I; Bental T; Battler A; Kornowski R
Am J Cardiol; 2012 Jun; 109(11):1563-8. PubMed ID: 22440117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
